Delicare Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 21-12-2024
- Paid Up Capital ₹ 1.31 Cr
as on 21-12-2024
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
as on 21-12-2024
- Revenue -75.91%
(FY 2022)
- Profit 101.22%
(FY 2022)
- Ebitda 746.64%
(FY 2022)
- Net Worth 0.07%
(FY 2022)
- Total Assets 2.91%
(FY 2022)
About Delicare Lifesciences
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.31 Cr.
The company currently has active open charges totaling ₹3.00 Cr.
Ashwani Deedwania, Sanchit Agarwal, Narayanlal Sarada, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74120MH2011PTC222686
- Company No.
222686
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Delicare Lifesciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanchit Agarwal  | Director | 27-Mar-2019 | Current |
| Ashwani Deedwania | Director | 26-May-2018 | Current |
| Narayanlal Sarada | Director | 26-May-2018 | Current |
| Jiggar Savla | Director | 06-Feb-2021 | Current |
| Nilesh Shah | Director | 16-Feb-2023 | Current |
Financial Performance of Delicare Lifesciences.
Delicare Lifesciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 75.91% decrease. The company also saw a substantial improvement in profitability, with a 101.22% increase in profit. The company's net worth moved up by a moderate rise of 0.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delicare Lifesciences?
In 2021, Delicare Lifesciences had a promoter holding of 39.01% and a public holding of 60.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Exeens Capital Advisors Private LimitedActive 6 years 9 monthsAshwani Deedwania and Sanchit Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 May 2019 | ₹1.00 Cr | Open |
Others Creation Date: 30 Mar 2019 | ₹1.00 Cr | Open |
Others Creation Date: 07 Feb 2019 | ₹1.00 Cr | Open |
How Many Employees Work at Delicare Lifesciences?
Unlock and access historical data on people associated with Delicare Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delicare Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delicare Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
